Skip to Content

XL184 20mg (Cometriq 20 mg)

Generic Name: cabozantinib

Pill with imprint XL184 20mg is Gray, Capsule-shape and has been identified as Cometriq 20 mg. It is supplied by Exelixis, Inc..

Cometriq is used in the treatment of thyroid cancer and belongs to the drug classes multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Cometriq 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for XL184 20mg

Cometriq

Generic Name:
cabozantinib
Imprint:
XL184 20mg
Strength:
20 mg
Color:
Gray
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Multikinase inhibitors
VEGF/VEGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Exelixis, Inc.
National Drug Code (NDC):
42388-0014

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide